Hot Growth Companies To Invest In Right Now

When investing client money, we use a combination of both value and growth stocks in client accounts, as well as using fundamental and technical analysis for timing entry and exit points for individual securities and ETFs.

Lately, we've had our eye on the Consumer Staples sector given Staples are now the most "oversold" sector of the S&P 500, outside of Telecom and Utilities, neither sector of which we usually traffic in for clients.

For a quick summary of the Consumer Staples sector in terms of what we are watching here are some "fast facts":

Staples are roughly 10% of the S&P 500 by market cap; Earnings growth is pretty consistently mid-single-digit for the sector, with the last 6 - 8 quarters seeing 3% to 10% growth; Revenue growth is typically low-single-digit for Staples, with currency playing a big role in beats / misses, although the upside / downside for revenues is usually just 1% -2 % range; The key to the sector is "stability and consistency" of both earnings and revenue growth, with typically very positive cash-flow and decent dividend yields and share repurchase programs;

We do like the Staples stocks, and like several at these price levels:

Hot Growth Companies To Invest In Right Now: Nordstrom Inc.(JWN)

Nordstrom, Inc., a fashion specialty retailer, offers apparel, shoes, cosmetics, and accessories for women, men, and children in the United States. It offers a selection of brand name and private label merchandise. The company sells its products through various channels, including Nordstrom full-line stores, off-price Nordstrom Rack stores, Jeffrey? boutiques, treasure & bond, and Last Chance clearance stores; and its online store, nordstrom.com, as well as through catalog. Nordstrom also provides a private label card, two Nordstrom VISA credit cards, and a debit card for Nordstrom purchases. The company?s credit and debit cards feature a shopping-based loyalty program. As of September 30, 2011, it operated 222 stores, including 117 full-line stores, 101 Nordstrom Racks, 2 Jeffrey boutiques, 1 treasure & bond store, and 1 clearance store in 30 states. The company was founded in 1901 and is based in Seattle, Washington.

Advisors' Opinion:

• [By Rich Duprey]

  Not that the actual service Kmart is providing is unique, mind you. Wal-Mart (NYSE: WMT  ) offers a free ship-to-store feature, as do J.C. Penney,�Radio Shack, Toys R Us,�Nordstrom� (NYSE: JWN  ) , and a number of other retailers. Actually, so committed to customer service is Nordstrom that it's even had employees drive items to a customer's house at no charge to ensure they get it.�

Hot Growth Companies To Invest In Right Now: Buffalo Wild Wings Inc.(BWLD)

Buffalo Wild Wings, Inc. engages in the ownership, operation, and franchise of restaurants in the United States. The company provides quick casual and casual dining services, as well as serves bottled beers, wines, and liquor. As of July 26, 2011, it had 773 Buffalo Wild Wings locations in 45 states in the United States, as well as in Canada. The company was founded in 1982 and is headquartered in Minneapolis, Minnesota.

Advisors' Opinion:

• [By Rick Munarriz]

  Buffalo Wild Wings (NASDAQ: BWLD  ) may have come up short on the bottom line for the fourth quarter in a row, but comps are picking up nicely at the chain of family-friendly sports bars.

• [By Dan Caplinger]

  Next Monday, Buffalo Wild Wings (NASDAQ: BWLD  ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed, knee-jerk reaction to news that turns out to be exactly the wrong move.

Hot Low Price Companies To Watch For 2014: Waste Management Inc.(WM)

Waste Management, Inc., through its subsidiaries, provides waste management services to residential, commercial, industrial, and municipal customers in North America. It offers collection, transfer, recycling, and disposal services. The company also owns, develops, and operates waste-to-energy and landfill gas-to-energy facilities in the United States. Its collection services involves in picking up and transporting waste and recyclable materials from where it was generated to a transfer station, material recovery facility, or disposal site; and recycling operations include collection and materials processing, plastics materials recycling, and commodities recycling. In addition, it provides recycling brokerage, which includes managing the marketing of recyclable materials for third parties; and electronic recycling services, such as collection, sorting, and disassembling of discarded computers, communications equipment, and other electronic equipment. Further, the company e ngages in renting and servicing portable restroom facilities to municipalities and commercial customers under the Port-o-Let name; and involves in landfill gas-to-energy operations comprising recovering and processing the methane gas produced naturally by landfills into a renewable energy source, as well as provides street and parking lot sweeping services. Additionally, it offers portable self-storage, fluorescent lamp recycling, and medical waste services for healthcare facilities, pharmacies, and individuals, as well as provides services on behalf of third parties to construct waste facilities. The company was formerly known as USA Waste Services, Inc. and changed its name to Waste Management, Inc. in 1998. Waste Management, Inc. was incorporated in 1987 and is based in Houston, Texas.

Advisors' Opinion:

• [By Maxx Chatsko]

  Consider that municipalities and industrial giants such as�Waste Management� (NYSE: WM  ) �are converting their fleets -- in this case garbage trucks -- to�run on natural gas fuels�(link opens a video). It's a little easier for Waste Management, since it uses biogas generated from its managed landfills to fuel its own vehicles. Clean Energy Fuels also sources biomethane from one of its landfills in Dallas. In fact, the facility can produce up to 36,000 gasoline-equivalent gallons�each day. It's like the old saying goes: One man's trash is another man's fuel.��

Hot Growth Companies To Invest In Right Now: Intuitive Surgical Inc.(ISRG)

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems for various surgical procedures, including urologic, gynecologic, cardiothoracic, general, and head and neck surgeries. Its da Vinci surgical system consists of a surgeon?s console or consoles, a patient-side cart, a 3-D vision system, and proprietary ?wristed? instruments. The company?s da Vinci surgical system translates the surgeon?s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments positioned inside the patient through small puncture incisions, or ports. It also manufactures a range of EndoWrist instruments, which incorporate wrist joints for natural dexterity for various surgical procedures. Its EndoWrist instruments consist of forceps, scissors, electrocautery, scalpels, and other surgical tools. In addition, it sells various vision and accessory products for use in conjunction with the da Vinci Surgical System as surgical procedures are performed. The company?s accessory products include sterile drapes used to ensure a sterile field during surgery; vision products, such as replacement 3-D stereo endoscopes, camera heads, light guides, and other items. It markets its products through sales representatives in the United States, and through sales representatives and distributors in international markets. The company was founded in 1995 and is headquartered in Sunnyvale, California.

Advisors' Opinion:

• [By WWW.GURUFOCUS.COM]

  Intuitive Surgical, Inc. (ISRG), which sells the da Vinci robotic surgical systems, fell 25.7% in the quarter when results fell short of expectations as growth in procedures slowed and unit placements declined. Hospital admissions have been weak and negative publicity affected the amount of procedures performed. We reduced our position in the stock by half this year, but now believe the stock is oversold and too cheap.

• [By Selena Maranjian]

  Among holdings in which Viking Global increased its stake was Intuitive Surgical (NASDAQ: ISRG  ) , a specialist in robotic surgical equipment. The company has had a bumpy year, thanks to bearish comments from a research firm and questions about the efficacy of its systems. Some legal worries were eased recently, with a victory in court. While some wonder whether the company's growth prospects are slowing down, others love Intuitive's competitive advantages and dominance in its promising market. It has been posting double-digit revenue and earnings growth rates for quite a while and has a forward P/E ratio near 23, which is not exactly nosebleed territory.

• [By Steve Symington and Alison Southwick]

  On the heels of Intuitive Surgical's (NASDAQ: ISRG  ) recent warning about weak capital spending in the U.S., MAKO Surgical (NASDAQ: MAKO  ) investors are worried that their up-and-coming company may not be able to meet its already conservative guidance when it reports earnings later this month.

Hot Growth Companies To Invest In Right Now: Checkpoint Systms Inc.(CKP)

Checkpoint Systems, Inc. manufactures and markets identification, tracking, security, and merchandising solutions for the retail and apparel industry worldwide. The company operates in three segments: Shrink Management Solutions, Apparel Labeling Solutions, and Retail Merchandising Solutions. The Shrink Management Solutions segment provides shrink management and merchandise visibility solutions. It offers electronic article surveillance systems, such as EVOLVE, a suite of RF and RFID-enabled products that act as a deterrent to prevent merchandise theft in retail stores; and electronic article surveillance consumables, including EAS-RF and EAS-EM labels that work in combination with EAS systems to reduce merchandise theft in retail stores. This segment also provides keepers, spider wraps, bottle security, and hard tags, as well as Showsafe, a line alarm system for protecting display merchandise. In addition, it offers physical and electronic store monitoring solutions, incl uding fire alarms, intrusion alarms, and digital video recording systems for retail environments; and RFID tags and labels. The Apparel Labeling Solutions segment provides apparel labeling solutions to apparel retailers, brand owners, and manufacturers. It has Web-enabled apparel labeling solutions platform and network of 28 service bureaus located in 22 countries that supplies customers with customized apparel tags and labels. The Retail Merchandising Solutions segment offers hand-held label applicators and tags, promotional displays, and queuing systems. The company serves retailers in the supermarket, drug store, hypermarket, and mass merchandiser markets through direct distribution and reseller channels. Checkpoint Systems was founded in 1969 and is based in Thorofare, New Jersey.

Advisors' Opinion:

• [By John Udovich]

  Small cap Checkpoint Systems, Inc (NYSE: CKP) fights shoplifting or retail theft and other forms of�"shrink��that costs retailers over $112 billion worldwide last year (according to a study funded by the company), meaning it might be an interesting stock to take a closer look at and to compare its performance with that of SPDR S&P Retail ETF (NYSEARCA: XRT) and PowerShares Dynamic Retail ETF (NYSEARCA: PMR). Just how bad can shoplifting or shrink be for a retailer? Troubled retailer J.C. Penney Company, Inc (NYSE: JCP) has just reported that shoplifting took a full percentage point off the department store chain's profit margins during the quarter. Moreover and given that tens of millions of Americans are now facing higher health insurance costs thanks to Obamacare (which will likely impact consumer discretionary spending),�retailers�will need to find ways to shore up their margins and bottom lines by preventing�retail theft with solutions from company�� like Checkpoint Systems.

• [By Rich Smith]

  Three months after settling upon a new chief executive officer, it looks like Thorofare, N. J.-based Checkpoint Systems (NYSE: CKP  ) will soon have itself a new CFO as well.

Hot Growth Companies To Invest In Right Now: Thoratec Corporation(THOR)

Thoratec Corporation engages in the development, manufacture, and marketing of proprietary medical devices used for circulatory support. The company?s primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge, and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising hom e discharge, and post-cardiotomy myocardial recovery. The company also provides CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure. In addition, it offers PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. The company sells its products through direct sales force in the United States, as well as through a network of distributors internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of medical device company Thoratec (NASDAQ: THOR  ) sank 12% today after its quarterly results missed Wall Street expectations. �

Mortgage Rates Rise Slightly, but Stay Near 3-Month Lows

Best Insurance Stocks To Watch For 2014

Matt York/AP WASHINGTON -- Average U.S. rates on fixed mortgages rose slightly this week, staying near three-month lows. Rates could fall next week now that lawmakers reached a deal to avert a possible government debt default and reopen the federal government. Mortgage buyer Freddie Mac said Thursday that the average rate on the 30-year loan increased to 4.28 percent from 4.23 percent last week. The average on the 15-year fixed loan edged up to 3.33 percent from 3.31 percent. Mortgage rates began falling last month after the Federal Reserve held off slowing its $85-billion-a-month in bond purchases. The bond buys are intended to keep longer-term interest rates low, including mortgage rates. And rates stayed relatively low during the 16-day partial government shutdown. Rates are likely to fall even lower now that Congress reached a deal to reopen the government and allow the Treasury to borrow normally until early February. Mortgage rates tend to follow the yield on the 10-year Treasury note. The 10-year note fell to 2.61 percent Thursday, down from 2.74 percent Tuesday.

Turnarounds and Bounce Bets

Over 80 stocks were featured in last year's Top Picks report. The very best performer? George Putnam. Here, the editor of The Turnaround Letter updates this top-performing stock pick and highlights some additional year-end bounce candidates.

Steve Halpern: We are here today with George Putnam, Editor of the Turnaround Letter. How are you doing, George?

George Putnam: Fine. Thanks, Steve.

Steve Halpern: Today, we're concluding a series of interviews with the top performing advisors from last year's Top Picks Report, and of the 81 stocks in that report, you had the number one performing pick, MGIC Investment, which is up about 215%. Congratulations.

George Putnam: Thank you very much.

Steve Halpern: Could you review the original reasoning for choosing MGIC last year and what has occurred during 2013 to account for the stock's strong performance?

George Putnam: Sure. Well, MGIC Investment Corp. (MTG), which insures mortgages—residential mortgages—was really hammered back in 2007, 2008, and it struggled to, sort of, dig out of the hole that it got in from all of the defaults that individual homeowners made on their mortgages.

But towards the end of last year, it raised some new capital to shore up its balance sheet and was showing signs that the past problems were really being handled, and so, the stock would turn the corner, and fortunately it did work out that way.

Steve Halpern: Now are these gains, that you think of, only those that occurred in the past, and people should be selling, or would you still recommend the stock, expecting better things to come?

George Putnam: No, I think the stock has further to go, because now that they've gotten the past problems largely behind them, they can focus on their new business, which has been going well and is highly profitable.

And also, people will finally recognize that this stock has a future, so they will be more willing to buy into it, so while it's done very well over the last year, I think it's got a fair amount further to go.

Steve Halpern: Now, as an expert in turnaround situations, you focus on very long-term fundamentals, often recommending a stock for years to come. But one exception to that pattern is, every December, you provide your subscribers with year-end bounce candidates. Could you explain that strategy?

George Putnam: Sure. Every year, around this time, you get a lot of selling pressure in certain stocks, and the pressure is really tied to the calendar. It comes from two sources.

Page 1 | Page 2 | Next Page The expert featured in this column, George Putnam, may or may not own positions in any investment vehicle mentioned here. The views and opinions expressed are his or her own.

How Capital Markets Will React to FOMC News

NEW YORK (TheStreet) -- In my opinion, Federal Reserve policy failed as soon as the FOMC cut the federal funds rate below 3% on March 18, 2008, to 2.25%. It was Dec. 16, 2008, when the Fed cut this rate to 0%, where it could remain for years to come if Janet Yellen becomes the next Fed chairman in early 2014.

The Fed's quantitative easing programs began in late November 2008 when the Federal Reserve Open Market Trading Desk in New York began to purchase $600 billion in mortgage-backed securities. Two years later the Fed announced another round of purchases and this time it was $600 billion in longer-dated U.S. Treasuries by the end of second quarter of 2011. This second wave was dubbed QE2. [Read: Before Buying ConAgra, Read the Label]

QE3 was announced on Sept. 13, 2012, and QE4 was announced on Dec. 12, 2012. QE3 is the purchase of $40 billion per month in mortgage-backed securities and QE4 added another $45 billion of longer-dated Treasuries per month. There has been talk that the Fed will begin to reduce these purchases following today's FOMC meeting. Some say yes, others say no, I say it doesn't matter as the program has failed in its objective, which is to lower mortgage rates.

Before QE3 and QE4 were implemented the yield on the Treasury 10-year note traded as low as 1.377% on July 25, 2012. The lowest point for this year is 1.612% set on May 1, just about the time when speculation began that the FOMC will likely taper securities purchases following today's FOMC meeting. The high yield in anticipation of tapering has been 3.007% set on Sept. 6. Instead of pushing mortgage rates lower as intended, the bond market became worried about future inflation that the massive QE's could create, and for this reason the combination of the QEs and the 0% federal funds rate has been a failed monetary policy. [Read: Affordable Care Act Reality Check] Continue to trade the bond market just like a stock using iShares 20+ Year Treasury Bond (TLT) ($103.71). The Treasury ETF remains below its 50-day simple moving average at $105.67 after setting a multi-year low at $102.11 on Aug. 21. The weekly chart shows an oversold condition with the five-week modified moving average at $105.25 and the 200-week SMA at $107.77. This week's value level is $100.96 with a monthly pivot at $105.75. My semiannual value level lags at $92.32 with annual risky levels at $116.26 and $120.42.

Continue to trade the gold market just like a stock using SPDR Gold Trust (GLD) ($126.50). The ETF is below its 50-day SMA at $129.14 with the 200-day SMA at $143.62. The weekly chart is negative with the five-week MMA at $129.81 and the 200-week SMA at $143.36. My monthly value level is $118.35 with a weekly risky level is $135.75.

Continue to trade crude oil using the Energy Select Sector SPDR Fund (XLE) ($84.31) The EFT traded to a new multi-year high at $84.66 on Monday. The 50-day and 200-day SMAs are supports at $82.41 and $78.61. The weekly chart is positive but overbought with the five-week MMA at $82.75 and the 200-week SMA at $68.78. My weekly value level is $81.68 with monthly and semiannual risky levels at $87.91 and $88.35.

For the major equity averages the Russell 2000 tested a new all-time high at 1066.39 at Tuesday's close. The Nasdaq set a new multi-year high at 3756.24 on Monday staying shy of my semiannual risky level at 3759. The other three major averages stayed below their all-time highs at 15,658.43 for the Dow Industrial Average, set on Aug. 2, 1709.67 for the S&P 500 set on Aug. 2 and 6686.86 Dow transportation average set on Aug. 1.

It seems highly likely that all five major averages will power to new highs given a positive reaction to the Fed statement and to comments by Ben Bernanke at his press conference this afternoon. [Read: Crunch Time for Gold Again] If the Nasdaq has a weekly close above 3759 the upside is to my semiannual risky levels at 16,490 Dow Industrial Average, 1743.5 on the S&P 500, 7104 Dow transports and 1089.43 on the Russell 2000. As I have said before, if you cannot confirm cycle highs, new highs will likely follow. SPDR Dow Jones Industrial Avg ETF Fund (DIA) ($155.29) is above its 50-day SMA at $152.68 with the 200-day SMA at $145.42 with the Aug. 2 high at $156.24. The weekly chart shifts to positive with a weekly close above the five-week MMA at $152.22. My weekly value level is $149.35 with monthly and semiannual risky levels at $163.25 and $164.06.

PowerShares QQQ Trust Series 1 (QQQ) ($78.37) is above its 50-day SMA at $76.06 with the 200-day SMA at $70.80 and set a multi-year high at $78.72 on Monday. The weekly chart is positive but overbought with the five-week MMA at $76.52. My quarterly value level is $73.00 with monthly and weekly pivots at $78.18 and $78.63 with semiannual risky levels at $79.76 and $80.87. [Read: HED-HERE]

SPDR S&P 500 ETF Trust (SPY) ($171.07) is above its 50-day SMA at $167.69 with the 200-day SMA at $157.92 and new all time high at $171.24 set on Monday. The weekly chart shifts to positive with a weekly close above its five-week MMA at $167.56. My weekly value level is $166.42 with a semiannual risky level at $174.10.

At the time of publication the author held no positions in any of the stocks mentioned.

Follow @Suttmeier This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.

Richard Suttmeier has an engineering degree from Georgia Tech and a master of science from Brooklyn Poly. He began his career in the financial services industry in 1972 trading U.S. Treasury securities in the primary dealer community. In 1981 he formed the Government Bond Department at LF Rothschild and helped establish that firm as a primary dealer in 1986. Richard began writing market research in 1984 and held positions as market strategist at firms such as Smith Barney, William R Hough, Joseph Stevens, and Rightside Advisors. He joined www.ValuEngine.com in 2008 producing newsletters covering the U.S. capital markets, and a universe of more than 7,000 stocks. Richard employs a "buy and trade" investment strategy and can be reached at RSuttmeier@Gmail.com.

Will Jony Ive Hold Back Apple?

With Steve Jobs now out of the picture, design guru Jony Ive is now more or less Apple's (NASDAQ: AAPL  ) main product guy. That's a role that Tim Cook was never destined to fill, but the good news is that Ive shared many design ideals with Jobs. With the upcoming version of iOS set to see its most dramatic aesthetic overhaul in the platform's history under Ive's direction, is Ive about to hold back Apple?

Bloomberg reports that Apple may be at risk of delaying iOS 7's release due to the sheer extent of changes that Ive is pursuing. The British-born designer is axing all signs of skeuomorphism in the operating system, burning down wooden bookshelves and ripping up the faux leather in every area where the cheesy approach has infiltrated the OS.

Ive reportedly wants to dramatically change the email and calendar apps, a decision that shouldn't be taken lightly as two of the most commonly used first-party apps among users. All in all, the changes are putting a strain on Apple's talent resources, and the company has redeployed some of its Mac software engineers to work on iOS.

Apple's Worldwide Developers Conference is just around the corner where iOS 7 will be unveiled and early builds will likely be distributed to developers shortly thereafter for testing. A full public release would likely come in September, in line with how the timing played out last year.

Other recent reports have indicated that Ive is going for a much flatter design philosophy, so much so that iOS may resemble Microsoft Windows Phone aesthetically. Other Apple insiders have also similarly hinted that iOS 7 is running behind schedule due to the dramatic overhaul.

This year's iOS should focus on refinement, although Apple may also have some new services up its sleeve. The two major services unveiled over the past two years, Siri and Maps, still need some work, but that might not stop the iPhone maker from launching an iRadio streaming service or mobile payments solution.

Even if Ive's overhaul results in some minor delays, it'll be worth the wait.

There's a debate raging right now: Is Apple still a buy? The Motley Fool's senior technology analyst and managing bureau chief, Eric Bleeker, is prepared to fill you in on reasons to buy and reasons to sell Apple, and what opportunities are left for the company (and your portfolio) going forward. To get instant access to his latest thinking on Apple, simply click here now.

I Did Better in the Long-Term Than the Short Run in 2013

As 2013 nears its end, MoneyShow's Howard R. Gold, takes a look back at his hits and misses of the past year, and looks forward to the ups and downs he'll experience in 2014, and in many more years to come.

It's almost time to sing Auld Lang Syne again, so, in this, my last column of the year, I'm presenting my annual recap of how I did.

I've been doing this report card for a few years out of accountability to you, the audience. I try to be as forthcoming as possible about my hits and misses.

So, looking over my columns in 2013 (and slightly before, since some major moves started in late 2012), I can say I got the big themes right—a continuing bull market in stocks; the irrelevance of the budget crisis in Washington, DC; the imminent danger facing bonds, and the persistent weakness of gold.

Unfortunately, my short-term record was mixed. And when I departed from long-held views, I lived to regret it.

First, the good news.

Last September, I cited several market gurus who "are starting to think the unthinkable: We may be entering a new secular bull market...that could take the averages much, much higher over several years."

I don't know about the next several years, but since then, the Standard & Poor's 500 index (SPX) has risen 24%.

And it's up 20.5% since I declared, in February 2013, that "the calendar is in investors' favor."

My first column of 2013 laid out four big themes:

1. The US economy will continue to grow.

2.The worst of the Eurozone's debt crisis is over.

3. US stocks will rise, but not as much as in 2012.

4. Emerging markets will outpace the US once again.

I got two and a half of them right. US stocks did rise—but much more than in 2012—outperforming emerging markets.

One thing I consistently got right was telling you to "stop obsessing over the fiscal cliff" or other Beltway budget battles. As I wrote in November 2012: "When nobody knows anything, the best thing to do is nothing at all...This brouhaha over the fiscal cliff is just noise that investors can safely ignore."

And in March, I wrote: "After two and a half years in which political events repeatedly shook markets…we're finally at the point where politics don't matter." Now that the Ryan-Murray budget deal has passed, I think that will be even more true in 2014.

Top Low Price Stocks To Invest In Right Now

This column also correctly identified assets for investors to sell or avoid.

Last September, I called long-term US Treasury bonds, Treasury Inflation-Protected Securities (which I bashed again in April), and high-yield bonds "the market's three most overvalued assets."

Read Howard's column on the market's three most overvalued assets on MoneyShow.com.

The iShares 20+ Year Treasury Bond ETF (TLT) has lost 14% of its value since then, while the TIP ETF has fallen 8%—big declines for supposedly "safe" bonds. The iShares iBoxx $ High Yield Corporate Bond ETF (HYG) has risen 7.9% since then, but has lagged stocks big time.

In May, I said real estate investment trusts (REITs) "have outperformed the S&P 500 for 11 of the last 16 quarters" and so "I'd be inclined to take at least some profits." That column ran pretty close to REITs' all-time high and the Vanguard REIT Index ETF (VNQ) has lost 11% of its value.

NEXT PAGE: Short-Term Ups and Downs

Page 1 | Page 2 | Next Page

Top 10 Medical Stocks To Watch For 2014

Both WellPoint and UnitedHealth Group reported strong earnings that beat Wall Street expectations, but both are cautious heading into the Affordable Care Act's full implementation in 2014. Increased membership and declining medical costs saw full-year earnings guidance improve, powering both stocks higher.�

However, on their respective conference calls it wasn't just positive earnings surprises and guidance raises. Management has distinct concerns over the impact that decisions coming from Washington, D.C., will have on their business. Specifically cuts to the Medicare Advantage program weighed heavily, but both companies see opportunity in Obamacare as well.

In this video, health-care analyst David Williamson discusses the quarterly highlights, key takeaways from each company's conference call, and whether investors should be optimistic about their company's performance for this year and next.

Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may affect your taxes, health insurance, and investments.�Click here�for your free copy today.

Top 10 Medical Stocks To Watch For 2014: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Top 10 Medical Stocks To Watch For 2014: Prosensa Holding NV (RNA)

Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.

Advisors' Opinion:

• [By John Udovich]

  Recent news surrounding small cap biotech stocks like�Xencor Inc (NASDAQ: XNCR), Prosensa Holding NV (NASDAQ: RNA),�Puma Biotechnology Inc (NYSE: PBYI),�Geron Corporation (NASDAQ: GERN)
  and TNI BioTech Inc (OTCQB: TNIB) show that while the sector and appetite for biotech�IPOs may have cooled, lottery tickets can still be found or occur in the sector. Just consider the following recent news or trends:

• [By Keith Speights]

  An "alley-oop" from the opponent
  Prosensa (NASDAQ: RNA  ) shares made something of a slam dunk this week, jumping more than 16%. That dunk was made with what amounts to an "alley-oop" from its primary rival, Sarepta Therapeutics (NASDAQ: SRPT  ) .

Top Warren Buffett Companies To Invest In 2014: DENTSPLY International Inc.(XRAY)

DENTSPLY International Inc. designs, develops, manufactures, and markets dental consumable products, dental laboratory products, and dental specialty products worldwide. The company?s dental consumable products include dental sundries, such as dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride; and small equipment, including high and low speed handpieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers used in dental offices for the treatment of patients. Its dental laboratory products comprise dental prosthetics, including artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials, as well as equipment, such as computer aided machining ceramic systems and porcelain furnaces used in the preparation of dental appliances by dental laboratories. The company?s dental specialty products consist of endodonti c instruments and materials, implants and related products, bone grafting materials, 3D digital implantology, and orthodontic appliances and accessories. Its customers include dentists, dental hygienists, dental assistants, dental laboratories, and dental schools. The company distributes its dental products directly to dental laboratories and dental professionals, as well as through distributors, dealers, and importers. DENTSPLY International Inc. was founded in 1983 and is headquartered in York, Pennsylvania.

Advisors' Opinion:

• [By Ben Levisohn]

  Shares of Align have surged 24% to $57 at 12:37 p.m. Sirona Dental Systems (SIRO) has risen 0.8% to $69.61, Dentsply International (XRAY) is up 0.1% at $45.44, Integra Lifesciences (IART) has� gained 0.4% to $44.23 and Danaher (DHR) has fallen 0.3% to $72.13.

• [By Sue Chang and William L. Watts]

  Dentsply International Inc. (XRAY) �shares rose 3%. The stock was raised to buy from underperform at Bank of America, according to Benzinga.

Top 10 Medical Stocks To Watch For 2014: RXi Pharmaceuticals Corp (RXII.PK)

RXi Pharmaceuticals Corporation (RXi), incorporated on September 8, 2011, is a development-stage company. The Company is a biotechnology company focused on discovering, developing and commercializing therapies addressing medical needs using RNA interference (RNAi)-targeted technologies. As of July 12, 2012, RXi was focusing on its internal therapeutic development efforts in fibrosis. RXI-109 is its RNAi product candidate, which is a dermal anti-scarring therapy that targets connective tissue growth factor (CTGF). The Company�� therapeutic platform consists of two main components: RNAi Compounds (rxRNA) and Advanced Delivery Technologies. RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self-delivering RNA. On April 26, 2012, it completed the spin-off transaction from Galena Biopharma, Inc. (Galena).

In January 2011, the Company announced research results in collaboration with Generex Biotechnology Corporation, and RXi�� wholly owned subsidia ry Antigen Express, Inc., in developing vaccine formulations for immunotherapy. In January 2011, it announced initial results as part of its collaboration with miRagen Therapeutics, Inc. in creating microRNA mimics, or artificial copies of microRNAs, using the Company�� sd-rxRNA technology. In February 2011, it announced the initiation of RXi�� development program for RXI-109.

Top 10 Medical Stocks To Watch For 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

• [By WALLSTCHEATSHEET.COM]

  Celgene has new drugs that should boost revenue. The pipeline potential is strong, profits have been growing, and guidance is good. If the market takes a hit, then Celgene will take a hit with it, but it should hold up better than most stocks throughout the broader market. If the market holds up or continues its relentless ascent, then Celgene should see future gains.

• [By Steven Silver]

  In our view, Amgen (AMGN), Celgene (CELG), and Gilead Sciences (GILD) each has bolstered its long-term growth prospects in recent years.

  Celgene, which had been reliant on its multiple myeloma drug Revlimid for the majority of its revenue, secured approval of internally-developed Pomalyst for late-stage multiple myeloma.

• [By John Udovich]

  Cramer Talks Up Biotech and Cancer Biotech in Particular. For what his opinion might be worth, MSNBC�� Mad Money host Jim Cramer recently commented that the 25 best-performing small cap stocks this year are "almost entirely biotech." He went on to point out that Celldex Therapeutics has been "just incredible��and that other companies to watch include Celgene Corporation (NASDAQ: CELG), ImmunoGen, Inc (NASDAQ: IMGN) and Onyx Pharmaceuticals, Inc (NASDAQ: ONXX), which all have promising cancer products on the way. He also added that:�

• [By Sean Williams]

  The current standard of treatment
  Celgene's (NASDAQ: CELG  ) Revlimid is the current shining star of multiple myeloma. Approved in 2006, Revlimid met its primary endpoint of extending time-to-progression when taken with dexamethasone in the first of two studies (median TTP of 37.1 weeks compared to just 19.9 weeks for the dexamethasone control arm). Sales of the drug have really taken off and accounted for $3.8 billion of Celgene's nearly $5.4 billion in product sales in 2012.

Top 10 Medical Stocks To Watch For 2014: Organovo Holdings Inc (ONVO.PK)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The C ompany has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an aut! om! ated device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Top 10 Medical Stocks To Watch For 2014: EntreMed Inc (ENMD.PH)

EntreMed, Inc. (EntreMed), incorporated in 1991, is a clinical-stage pharmaceutical company. EntreMed's drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed Phase I studies in patients with advanced solid tumors, multiple myeloma and leukemia and is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. The Company�� other product candidates have includes MKC-1, ENMD-1198 and 2-methoxyestrdiol (2ME2, Panzem) for treatment of rheumatoid arthritis.

ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases. ENMD-2076 is relatively selective for the Aurora A isoform in comparison to Aurora B. Aurora kinases are key regulators of the process of mitosis, or cell division, and are often over-expressed in human cancers. E NMD-2076 exerts its effects through multiple mechanisms of action, including anti-proliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated significant, dose-dependent preclinical activity as a single agent, including tumor regression, in multiple xenograft models (such as breast, colon, leukemia), as well as activity towards ex vivo-treated human leukemia patient cells.

Top 10 Medical Stocks To Watch For 2014: Universal Biosensors Inc (UBI)

Universal Biosensors, Inc. (Universal Biosensors) is an early-stage specialist medical diagnostics company focused on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. The Company uses its electrochemical cell technology platform to develop tests for a number of different markets. The Company�� principal activities are research and development, commercial manufacture of approved medical or testing devices and the provision of services including contract research work. The Company operates primarily in Australia. The Company uses its electrochemical cell technology platform to develop tests for a number of different markets. The Company has rights to a portfolio comprising patent applications owned by its wholly owned subsidiary, Universal Biosensors Pty Ltd, and a number of patents and patent applications licensed to the Company by LifeScan, Inc., an affiliate of Johnson & Johnson Company. Advisors' Opinion:

• [By Namitha Jagadeesh]

  Banco Popolare SC (BP) declined 3.5 percent to 1.29 euros and Unione di Banche Italiane SCPA (UBI) slid 2.3 percent to 4.93 euros after Societe Generale SA reduced its 12-month price forecast on the shares.

Top 10 Medical Stocks To Watch For 2014: Boston Scientific Corp (BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.

Interventional Cardiology

The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.

The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.

Cardiac Rhythm Management

The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.

Endoscopy

The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.

T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.

Peripheral Interventions

The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.

The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.

Urology/Women�� Health

The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.

The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.

Neuromodulation

The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.

Electrophysiology

The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.

The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.

Advisors' Opinion:

• [By Dan Caplinger]

  How the industry is responding
  Even before the tax took effect, companies took steps to reduce its potential impact. Stryker said last November that it would lay off 5% of its workforce in order to save $100 million in costs. Medtronic shifted most of its hiring toward overseas operations, while Boston Scientific (NYSE: BSX  ) announced layoffs last July only to announce immediately thereafter its plans to invest $150 million in China.

Top 10 Medical Stocks To Watch For 2014: StemCells Inc (STEM)

StemCells, Inc. (StemCells), incorporated in August 1988, is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�� primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�� human liver cells as a therapeutic product.

CNS Program

The Company in its CNS Program, is in clinical development with its HuCNS-SC cells for a range of disorders of the central nervous system. The CNS includes the brain, spinal cord and eye. In February 2012, the Company had completed a Phase I clinical trial in Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain.

The Company�� CNS Program is focused on developing clinical applications, in which transplanting HuCNS-SC cells protect or restore organ function of the patient before such function is irreversibly damaged or lost due to disease progression. The Company�� initial target indications are PMD, and more generally, diseases in which deficient myelination plays a central role, such as cerebral palsy or multiple sclerosis; spinal cord injury, disorders in which retinal degeneration plays a central role, such as age-related macular degeneration or retinitis pigmentosa. The Company�� product candidate, HuCNS-SC cells, is a purified and expanded composition of normal human neural stem cells. Its HuCNS-SC cells can be directly transp! lanted.

Liver Program

Liver stem or progenitor cells offer an alternative treatment for liver diseases. A liver cellular therapy or cell-based therapeutic provide or support liver function in patients with liver disease. The Company held a portfolio of issued and allowed patents in the liver field, which cover the isolation and use of both hLEC cells and the isolated subset, as well as the composition of the cells themselves.

The Company�� range of cell culture products, which are sold under the SC Proven brand, includes iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2, and NDiff N2B27. Its iSTEM is a serum-free, feeder-free medium that maintains mouse embryonic stem cells in their pluripotent ground state by using selective small molecule inhibitors to block the pathways, which induce differentiation. RHB-A is a defined, serum-free culture medium for the selective culture of human and mouse neural stem cells and their maintenance and expansion as adherent cell populations. RHB-Basal is a defined, serum-free basal medium. When supplemented with specific growth factors, this media is formulated for the propagation and differentiation of adherent neural stem cells. RHB-Basal can also be tailored to specific-cell type requirements by the addition of customer preferred supplements.

The Company�� NDiff N2 is a defined serum-free scell culture supplement for the derivation, maintenance, expansion and/or differentiation of human and mouse embryonic stem (ES) cells and tissue-derived neural stem cells supplement. Its NDiff N2-AF is a serum-free and animal component-free version of NDiff N2. Its NDiff N2B27 is a defined, serum-free medium for the differentiation of mouse embryonic stem cells to neural cell types. NDiff N27-AF is a serum-free and animal component-free version of NDiff N27. Its GS1-R is a serum-free media formulation shown to enable the derivation and long-term maintenance of true, germline competent rat embryonic stem cells without the add! ition of ! cytokines or growth factors. Its GS2-M is a defined, serum- and feeder-free medium for the derivation and long-term maintenance of true, germline competent mouse iPS cells.

The Company also markets a number of antibody reagents for use in cell detection, isolation and characterization. These reagents are also under the SC Proven brand and it includes STEM24, STEM101, STEM121 and STEM123. Its STEM24 is a human antibody that recognizes human CD24, also known as heat stable antigen (HSA), a glycoprotein expressed on the surface of many human cell types, including immature human hematopoietic cells, peripheral blood lymphocytes, erythrocytes and many human carcinomas. Its CD24 is also a marker of human neural differentiation. Its STEM101 is a human-specific mouse antibody that recognizes the Ku80 protein found in human nuclei. Its STEM121 is a human-specific mouse antibody that recognizes a cytoplasmic protein of human cells. Its STEM123 is a human-specific mouse antibody that recognizes human glial fibrillary acidic protein (GFAP).

The Company�� Other products marketed under SC Proven include total cell genomic DNA (gDNA), RNA and protein lysate reagents purified from homogenous stem cell populations for intra-comparative studies, such as Epigenetic fingerprinting, Southern, Western and Northern blots, PCR, RT-PCR and microarrays. This range of purified stem cell line lysates includes mouse embryonic stem (ES) cells propagated in SC Proven 2i inhibitor-based GS2-M media and mouse ES cell-derived and fetal tissue-derived neural stem (NS) cells propagated in SC Proven RHB-A media.

Advisors' Opinion:

• [By James E. Brumley]

  When an investor thinks of spinal-related stem cell stocks, usually a name like Neuralstem, Inc (NYSEMKT: CUR) or StemCells Inc (NASDAQ: STEM) comes to mind. And well they should. STEM has logged some amazing breakthroughs in the field of spinal cord repair, while CUR has done the same. Not all back problems are spinal cord related though. In fact, most back problems - and therefore the most opportunity - are bone and disc related problems. That's where a young gun like BioRestorative Therapies (OTCBB: BRTX) can step in and make stem cell waves. BRTX has developed an approach to rejuvenate and revive failing spinal discs, potentially ending pain for millions of back-pain sufferers, and circumventing expensive spinal surgeries that are in increasing burden on insurance companies.

• [By John Udovich]

  The results of a recent Pew Center Poll regarding attitudes towards abortion and various forms of stem cell research could be a good sign for the stem cell industry along with small cap stem cell stocks like StemCells Inc (NASDAQ: STEM), NeoStem Inc (NASDAQ: NBS), Neuralstem, Inc (NYSEMKT: CUR),�International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX). Basically, Americans think that having an abortion is a moral issue with 49% of American adults believing abortion is morally wrong, 23%�view it not as a moral issue and and 15% view it as morally acceptable. However and when Americans were asked about issues surrounding�human embryos, such as stem cell research or in vitro fertilization, as a matter of morality, their views were different.

Signs of a Top?

Although cycles do not give an exact inflection point for when a bull market will come to an end, they tend to be in the ballpark. Comparing the current bull market to that of the 2002-2007 market cycle suggests caution, says Joon Choi in Systems & Forecasts.

First, here's a recap of my recent comments on why we may be nearing a stock market top.

Corporations in the US have been buying back their shares at an alarming rate. The primary reasons for the buybacks are to increase the underlying share price, and to decrease the number of outstanding shares so companies will be able to engineer artificially higher earnings per shares.

Even with falling earnings, a company can manage a higher EPS if it buys back significant shares of its company.

Moreover, only 52% of S&P 500 Index (SPX) members were able to beat the analysts' estimates for the third quarter, far lower than the 70% average. In short, US companies are not doing as well as stock prices would suggest.

Also, initial public offerings have been rising in recent years and companies have raised $49.4 billion from IPO's so far this year—which is higher than the $48.7 billion raised in 2007. IPO activities tend to top out during stock market tops, as it did in 2000 and 2007.

Stock market lows were made in September of 2002 (based on monthly close) and the highs were made 61 months later in October of 2007.

February of 2009 was the stock market bottom for the recent bear market and 61 months later puts us at March of 2014. Thus, if the current bull market resembles the previous one, then the stock market top is only a few months away.

Uncertainty surrounding the debt ceiling debate (February 8, 2014 deadline), and the possibility of the Fed tapering off bond purchases, may lead to more volatility in the first quarter of next year.

Meanwhile, our proprietary models indicate that we are in a favorable environment for equities. However, I want to reiterate that a 5% sell-off in the equity market may turn into a double-digit correction.

Subscribe to Systems & Forecasts here…

More from MoneyShow.com:

Is it Time to be Fearful?

Dividend Theory Suggests Caution

Coppock Curve: Caution Sign?

Best Cheap Stocks To Buy Right Now

Getty Images No matter how budget-savvy you are, there's no avoiding the fact that having children is expensive. But with the help of your smartphone, you can cut your kid-related costs down considerably. Here are six apps that will help. Grocery iQ (free; iOS, Android): After housing and transportation, food is often the biggest chunk of a family's budget. Keep your grocery bill in check with this free app. Grocery iQ works with many major grocery chains, allowing you to organize your list around your favorite store's specific layout. Once you input your list, the app will calculate your total, so you can adjust it before you hit the checkout counter. Best of all, the app includes coupons (which can be linked with the store's loyalty card) to help you cut down your bill even more. Sample savings: 55 cents off Skippy peanut butter at my local Safeway (SWY). Out To Eat With Kids (free; iOS, Android): Don't feel like cooking tonight? Search this new app, which uses your location to find kid-friendly restaurant deals like "kids eat free" nights and seasonal promotions. It's also searchable by the day of the week. Most of the offers are for popular chain restaurants, but you can request that they add your family's favorite dinner spot. Sample savings: $4.79 off on a kid's meal during Moe's Southwest Grill's Tuesday night "Kids Eat Free" promotion. Chore Bank ($1.99; iOS): Why hire someone to rake the leaves or clean the house when you have free labor available right at home? Inspire your kids to pick up extra chores with Data Jedi's Chore Bank app, which allows parents to set a price for various tasks, then add that amount to the child's virtual account. The app can also track allowance and other money -- say, earnings from babysitting jobs or monetary gifts from relatives -- and deposits and withdrawals so your offspring can see where their money goes. You can even set an interest rate on savings to help kids learn the power of savings. Sample savings: $20-plus per week if you get your teen to mow the lawn instead of hiring a service. No more arguments about allowance? Priceless. Gas Buddy (free; iOS, Android, Windows phone, Blackberry): If, like many parents, your car is essentially a taxi service for your offspring, you're throwing money down the drain if you're not using this popular app. Gas Buddy easily finds the cheapest gas based on your location, so you'll never pay more at the pump than you have to. The prices are reported and confirmed by local drivers -- Gas Buddy reports it has more than 32 million users -- if you participate, you can earn points toward free gas. Sample savings: 54 cents a gallon on regular gas (the difference between the highest and lowest prices in my zip code). The Find (free; iOS, Android): Chances are, this time of year, your shopping list gets even longer than usual. Comparing prices from store to store, and asking for price matches, can save you a lot when holiday shopping. But who has time? This free app does it all for you: Just scan the barcode and watch as both online and local store prices pop up. Best Buy (BBY) and Target (TGT) are even working with the app's publisher to integrate their price-match guarantees with the iOS version. The app also includes coupons, deals (such as free shipping offers), and allows you to set price alerts when your wishlist items go on sale. Sample savings: $15 on the Lego City Town Square set on my son's Christmas list ($135 at Toys R Us, but only $120 at Lego.com). Best Baby Monitor ($3.99; iOS): A good-quality video monitor can do a lot to ease new parents' anxiety over their baby's sleep, but peace of mind doesn't come cheap. Enter Best Baby Monitor, truly a godsend app for new parents, and a real bargain if you already own a few iDevices. (It works on the iPhone, iPad, and iPod Touch. You'll need two devices to use this -- one to serve as the "parent" unit and the other to monitor the baby.) Parents can stream audio and video of their child (complete with night vision), play lullabies to soothe reluctant sleepers, talk to their babies, and get an alert when the little one wakes. Sample savings: $90 off a comparable video monitor system at Amazon.com (AMZN). Add it up and you could save more than $130 -- enough for a dinner out and a full tank of gas -- all thanks to a few apps.

Best Cheap Stocks To Buy Right Now: UnitedHealth Group Incorporated(UNH)

UnitedHealth Group Incorporated provides healthcare services in the United States. Its Health Benefits segment offers consumer-oriented health benefit plans and services to national employers, public sector employers, mid-sized employers, small businesses, and individuals; and non-employer based insurance options for purchase by individuals. It also provides health and well-being services for individuals aged 50 and older; and for services dealing with chronic disease and other specialized issues for older individuals, as well as health plans for the beneficiaries of acute and long-term care Medicaid plans. This segment offers its services through a network of 730,000 physicians and other health care professionals, and 5,300 hospitals. Its OptumHealth segment provides health, financial, and ancillary services and products that assist consumers through personalized health management solutions; benefit administration, and clinical and network management; health-based financi al services; behavioral solutions; and specialty benefits, such as dental, vision, life, critical illness, short-term disability, and stop-loss product offerings. The company?s Ingenix segment offers database and data management services, software products, publications, consulting and actuarial services, business process outsourcing services, and pharmaceutical data consulting and research services. Its Prescription Solutions segment provides integrated pharmacy benefit management services comprising retail network pharmacy contracting and management, claims processing, mail order pharmacy services, specialty pharmacy, benefit design consultation, rebate contracting and management, drug utilization review, formulary management programs, disease therapy management, and adherence programs to employer groups, union trusts, managed care organizations, Medicare-contracted plans, Medicaid plans, and third party administrators. The company was founded in 1974 and is based in Minne tonka, Minnesota.

Advisors' Opinion:

• [By Dan Dzombak]

  Today's Dow leader
  Today's Dow leader is UnitedHealth (NYSE: UNH  ) , up 6.4%. UnitedHealth reported that its earnings rose by 8% to $1.40 per share, beating analyst expectations of $1.25 per share. Revenue rose 12% to $30.41 billion, slightly below analysts' estimates of $40.52 billion. The large rise in revenue and earnings owed to the addition of 3.2 million new members in the quarter. UnitedHealth also upped its full-year guidance for the year to $5.35 to $5.50 per share from its previous guidance of $5.25 to $5.50 per share.

• [By WALLSTCHEATSHEET.COM]

  UnitedHealth Group is a health and well-being company that provides essential healthcare services during a critical time in the United States. The stock has witnessed a promising move higher that has taken it to all-time high prices, where it may consolidate before coasting higher. Over the last four quarters, earnings and revenue numbers have been on the rise, but investors have not been too pleased with the company’s reports. Relative to its peers and sector, UnitedHealth Group has been a year-to-date performance leader. Look for UnitedHealth Group to OUTPERFORM.

Best Cheap Stocks To Buy Right Now: Global Payments Inc.(GPN)

Global Payments Inc. provides electronic transaction processing services for merchants, independent sales organizations (ISO), financial institutions, government agencies, and multi-national corporations located in the United States, Canada, Europe, and the Asia-Pacific region. It offers a comprehensive line of processing solutions for credit and debit cards; business-to-business purchasing cards; gift cards; and electronic check conversion and check guarantee, verification, and recovery, including electronic check services, as well as terminal management. The company also offers proprietary software products to establish revolving check cashing limits for the casinos? customers in the gaming industry. In addition, it sells, installs, and services automated teller machine and point of sale terminals; and provides card issuing services, including card management and card personalization. The company markets its products directly, as well as through ISOs, retail outlets, tra de associations, alliance bank relationships, and financial institutions. Global Payments Inc. has a joint venture with La Caixa Group to provide merchant acquiring services to merchants in Spain. Global Payments Inc. was founded in 2001 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:

• [By Ben Levisohn]

  Global Payments�(GPN) has gained 6.8% to $54.12 in pre-open trading after the payment processing company reported a profit of $1 a share, beating analyst forecasts of 95 cents. It also said it would buy back stock.

• [By Monica Gerson]

  Global Payments (NYSE: GPN) is expected to post its Q1 earnings at $0.95 per share on revenue of $623.79 million.

  Synergetics USA (NASDAQ: SURG) is projected to post its Q4 earnings at $0.06 per share on revenue of $17.01 million.

Hot Growth Stocks To Own Right Now: Oracle Corporation(ORCL)

Oracle Corporation, an enterprise software company, develops, manufactures, markets, distributes, and services database and middleware software, applications software, and hardware systems worldwide. It licenses of database and middleware software, including database management software, application server software, service-oriented architecture and business process management software, data integration software, business intelligence software, identity and access management software, content management software, portals and user interaction software, development tools, and Java; and applications software comprising enterprise resource planning, customer relationship management, enterprise performance management, supply chain management, business intelligence applications, enterprise portfolio project management, Web commerce, and industry-specific applications software. The company also offers customers with rights to unspecified software product upgrades and maintenance releases; Internet access to technical content; and Internet and telephone access to technical support personnel. In addition, its hardware systems products consist of computer server and hardware-related software, including the Oracle Solaris Operating System; and storage products, such as tape, disk and networking solutions for open systems and mainframe server environments. Its hardware systems support solutions include software updates for the software components. Further, the company offers consulting solutions in business and IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancements and upgrades; cloud services, including Oracle Cloud Services and Advanced Customer Services; and education solutions comprising instructor-led, media-based, and Internet-based training in the use of its software and hardware products. The company was founded in 1977 and is headquartered in Redwood Ci ty, California.

Advisors' Opinion:

• [By Chuck Carnevale]

  If you examine most of our greatest technology names, you discover that as a sector they are trading at below market valuations. Yet, as a sector, they have produced the strongest historical growth and are expected to produce some of the strongest future growth as well. Today we find Microsoft (MSFT) trading at a PE ratio of 11, Oracle (ORCL) at a PE ratio of 12.9, and Hewlett-Packard (HPQ) can be bought at a PE of only 7. Even the mighty Apple (AAPL) computer only trades at a PE ratio of 15. These appear to be extremely low valuations when you consider both the importance and the promise of the technology sector�� contribution to our future.

Best Cheap Stocks To Buy Right Now: Wendy's/Arby's Group Inc.(WEN)

The Wendy's Company operates as a quick-service hamburger company in the United States. The company, through its subsidiary, Wendy's International, Inc., operates as a franchisor of the Wendy's restaurant system. As of December 26, 2011, the Wendy's system comprised approximately 6,500 franchise and company restaurants in the United States and the United States territories, as well as in 26 other countries worldwide. The company was formerly known as Wendy's/Arby's Group, Inc. and changed its name to The Wendy's Company in July 2011. The Wendy's Company was founded in 1884 and is headquartered in Dublin, Ohio.

Advisors' Opinion:

• [By Ben Levisohn]

  Upgrades had a big impact on stocks today. Wendy’s (WEN), for instance, gained 4.5% to $8.62 after being upgraded to Buy at Argus, while Cash America (CSH) advanced 3.7% to $44.32 after being upgraded to Market Outperform from Market Perform at JMP Securities. Walgreen (WAG) proved the big winner in the S&P 500 after�Goldman Sachs called the stock a Conviction Buy.

• [By Douglas A. McIntyre]

  Burger Kind has few advantages over its much larger�rival McDonald’s Corp. (NYSE: MCD), which has almost 13,000 locations in the United States.�Burger King has just�over 7,000. Wendy’s Co. (NYSE: WEN) is gaining with almost 6,000 stores. Burger King’s sales last year were less than $2 billion, in contrast to McDonald’s sales of $27.5 billion.

• [By Matt Brownell]

  Getty Images Not all is happy in McDonaldland. McDonald's reported its first-quarter earnings Friday morning, and while profit rose slightly, comparable-store sales in the U.S. fell 1.2%. Things were even worse abroad, with comparable sales in Asia, the Middle East and Africa falling 3.3%. In a statement accompanying the filing, McDonald's (MCD) CEO Don Thompson cited "global economic headwinds" and a "challenging eating-out environment." The poor sales don't come as a complete shock. While the company reported improved profits in the fourth quarter of 2012, it also saw sales decline in key foreign markets and dealt with a drop in operating profit margins. Though popular, the McRib barbecue sandwich can't solve all of the chain's problems. So in recent months, McDonald's has introduced Chicken McWraps in a bid to stimulate sagging sales. But franchisees recently complained that the sandwiches took too long to prepare. And the company is also confronting the fact that customer-service issues are rampant at its franchises: According to one report, McDonald's officials told franchisees that "service is broken." QSR Magazine, an industry trade publication, found that the average wait time at the McDonald's drive-through window was a full minute slower than at rival Wendy's (WEN). McDonald's stock dropped by more than 2 percentage points to $99.76 a share in pre-market trading.

  Tucked away at the McDonald's C.O.B. — or Campus Office Building — is the test kitchen, where the fast food chain comes up with all sorts of products.

• [By Sean Williams]

  The last fast-food chains standing
  If Jack in the Box (NASDAQ: JACK  ) and Wendy's (NASDAQ: WEN  ) can manage to go a few weeks without sticking their foot in the their mouth, they both have a shot at picking up market share based on these PR gaffes from McDonald's and Burger King.

Best Cheap Stocks To Buy Right Now: S&P GSCI(GD)

General Dynamics Corporation, an aerospace and defense company, provides business aviation; combat vehicles, weapons systems, and munitions; military and commercial shipbuilding; and communications and information technology products and services worldwide. Its Aerospace group designs, manufactures, and outfits various large and mid-cabin business-jet aircraft; provides maintenance, repair work, fixed-based operations, and aircraft management services; and performs aircraft completions for aircraft. The company?s Combat Systems group offers tracked and wheeled military vehicles, weapons systems, and munitions. Its product lines include wheeled combat and tactical vehicles; battle tanks and infantry vehicles; munitions and propellant; rockets and gun systems; and axle and drivetrain components and aftermarket parts. This group also manufactures and supplies engineered axles, suspensions, and brakes for heavy-load vehicles for military and commercial customers. The company Advisors' Opinion:

• [By Rich Smith]

  Armaments destined for the Iraqi military include Textron (NYSE: TXT  ) Bell 412 EP transport helicopters -- a dozen of them. Also, 50 M1135 Stryker wheeled armored personnel carriers from General Dynamics (NYSE: GD  ) , outfitted for survivability in a chemical warfare environment. And finally, a shipment of spare parts to be used in maintaining everything from Humvees to howitzers to heavy equipment for salvaging damaged tanks from the battlefield.

• [By Monica Gerson]

  General Dynamics (NYSE: GD) is expected to report its Q3 earnings at $1.68 per share on revenue of $7.76 billion.

  Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Best Cheap Stocks To Buy Right Now: SMTC Corporation(SMTX)

SMTC Corporation provides advanced electronics manufacturing services to original equipment manufacturers (OEMs) worldwide. The company?s services include product design and engineering services, printed circuit board assembly production, enclosure fabrication, systems integration, testing, and configuration services. It also provides enclosure and precision metal fabrication, cable assembly, interconnect, and engineering design services. The company offers its integrated contract manufacturing services to OEMs and technology companies primarily in the industrial, computing and networking, communications, consumer, and medical market segments. SMTC Corporation was founded in 1985 and is based in Markham, Canada.

Best Cheap Stocks To Buy Right Now: Capstone Turbine Corporation(CPST)

Capstone Turbine Corporation develops, manufactures, markets, and services turbine generator sets and related parts for use in stationary distributed power generation applications. Its stationary distributed power generation applications include cogeneration combined heat and power (CHP), integrated (CHP), resource recovery, and secure power, as well as combined cooling, heat, and power; and its products are used as battery charging generators for hybrid electric vehicle applications. The company primarily offers microturbine units, subassemblies, and components. It also provides various accessories, including rotary gas compressors with digital controls, heat recovery modules for CHP applications, dual mode controllers that allow automatic transition between grid connect and stand-alone modes, batteries with digital controls for stand-alone/dual-mode operations, power servers for multipacked installations, and protocol converters for Internet access, as well as frames, ex haust ducting, and installation hardware. Further, it remanufactures microturbine engines; and provides after-market parts and services, scheduled and unscheduled maintenance, and factory and on-site training services. The company?s microturbines can be fueled by various sources, including natural gas, propane, sour gas, landfill or digester gas, kerosene, diesel, and biodiesel. It primarily sells its products directly to end users, as well as through distributors in North America, Asia, Australia, Europe, the Russian Federation, and South America. Capstone Turbine Corporation was founded in 1988 and is based in Chatsworth, California.

Advisors' Opinion:

• [By Tyler Crowe and Aimee Duffy]

  Over the past couple weeks Capstone Turbine (NASDAQ: CPST  ) shares have launched into orbit on the news that the company had secured several orders for its microturbines. But 40% in a month? On the surface, it seems a bit silly that a company could gain that much on a couple news stories about sales. For a company like Capstone, which has struggled with sales, this kind of news is exactly what shareholders were looking for.

• [By Selena Maranjian]

  Fisher reduced its stake in lots of companies, including Capstone Turbine (NASDAQ: CPST  ) and Nokia (NYSE: NOK  ) . Capstone is a smallish company, making low-emission microturbines used in power generation. Its top line has been growing by double digits over the past few years, and it's poised to profit from huge interest in shale oil, but it remains in the red. Still, it has recently announced a bunch of promising deals and some think the many folks short the stock will end up burned.

• [By Tyler Crowe]

  What:�Shares of Capstone Turbine (NASDAQ: CPST  ) skyrocketed 13.59% as the company announced that it had signed a major supplier deal with private real estate and investment firm Related Companies. Shares of Capstone haven't been this high in over a year.

Best Cheap Stocks To Buy Right Now: Cloud Peak Energy Inc(CLD)

Cloud Peak Energy Inc., through its subsidiaries, engages in coal mining operations in the Powder River Basin of the United States. It produces sub-bituminous steam coal with low sulfur content for electric utilities and industrial customers. The company owns and operates Antelope surface coal mine located to the south of Gillette, Wyoming; the Cordero Rojo surface coal mine located to the south of Gillette, Wyoming; and the Spring Creek surface coal mine located in Montana. It also owns a 50% interest in the Decker surface coal mine located in Montana. As of December 31, 2010, it had approximately 970 million tons of proven and probable reserves. The company was founded in 1993 and is headquartered in Gillette, Wyoming.

Advisors' Opinion:

• [By Ben Levisohn]

  Cloud Peak Energy (CLD) has gained 3.1% to %15.03 after it was upgraded to Buy from Hold at Stifel.

  Novatris (NVS) has dropped 1.2% to $74.48 after it was downgraded to Neutral from Overweight at JP Morgan.